Kinnate Biopharma Revenue and Competitors

Claim your profile

Location

#6410

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Kinnate Biopharma's estimated annual revenue is currently $12.9M per year.(i)
  • Kinnate Biopharma's estimated revenue per employee is $158,827
  • Kinnate Biopharma's total funding is $194.5M.
  • Kinnate Biopharma's current valuation is $678.6M. (January 2022}

Employee Data

  • Kinnate Biopharma has 81 Employees.(i)
  • Kinnate Biopharma grew their employee count by 53% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$27.4M146-5%$160MN/A
#2
$3.7M24N/AN/AN/A
#3
$18.1M93-3%$24.1MN/A
#4
$47.1M304-3%N/AN/A
#5
$48.1M28014%$403MN/A
#6
$459.2M206854%$242.6MN/A
#7
$0.9M14133%$6.1MN/A
#8
$14.9M79-12%$140MN/A
#9
$29M187-1%N/AN/A
#10
$3.7M24N/AN/AN/A

Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers. Our mission is to expand the reach of targeted therapeutics by developing products for underserved populations. We utilize our deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which we refer to as our Kinnate Discovery Engine, to develop targeted therapies. Headquartered in San Diego, the Kinnate team is composed of drug discovery experts supported by world-class scientific advisors and investors. For more information, please visit www.kinnate.com.

keywords:N/A

$194.5M

Total Funding

81

Number of Employees

$12.9M

Revenue (est)

53%

Employee Growth %

$678.6M

Valuation

N/A

Accelerator

Kinnate Biopharma News

2022-04-17 - Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 ...

(Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for...

2022-04-17 - Kinnate Biopharma Inc. Announces First Patient Dosed in Phase 1 ...

SAN FRANCISCO and SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical...

2022-04-17 - Kinnate Biopharma begins dosing in phase 1 trial of KIN-3248 in advanced tumors

Kinnate Biopharma (NASDAQ:KNTE) said the first patient began treatment in a phase 1 trial of KIN-3248 in adults with advanced tumors...

2021-05-18 - Kinnate Biopharma Joint Venture Raises Usd35 Million in Series A Financing

Kinnate Biopharma Inc. has raised USD 35 million Series A financing for a joint venture in China. The financing was led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital. Kinnate Biopharma will be the majority shareholder in the joint venture. The ...

2021-05-13 - KINNATE BIOPHARMA INC. Kinnate Biopharma Inc :. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture

Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital The joint venture will have exclusive license to develop and commercialize Kinnate’s currently most advanced kinase inhibitor candidates in Greater China Veteran biopharmaceutical i ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A819%N/A
#2
$9.9M818%N/A
#3
$11.7M8111%N/A
#4
N/A81-36%N/A
#5
$12.9M81-8%$23.1M